89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

I C Kok, J A Hooiveld, P P van de Donk, D Giesen,E L van der Veen,M N Lub-de Hooge,A H Brouwers,T J N Hiltermann,A J van der Wekken, L B M Hijmering-Kappelle,W Timens,S G Elias,G A P Hospers,H J M Groen,W Uyterlinde,B van der Hiel,J B Haanen,D J A de Groot,M Jalving,E G E de Vries

Annals of Oncology（2022）

引用 43|浏览36

暂无评分

摘要

•89Zr-pembrolizumab PET imaging is safe and feasible in patients with metastatic melanoma and NSCLC.•89Zr-pembrolizumab uptake in tumor lesions correlates with response to PD-1 antibody treatment.•Patients with high 89Zr-pembrolizumab tumor uptake experience longer progression-free survival and overall survival.

查看译文

关键词

pembrolizumab,89Zr,PET,immunotherapy,PD-1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要